Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
BioMarin Pharmaceutical (BMRN) Stock Price & Analysis
1,643 Followers
BMRN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$70.73 - $117.77
Previous Close$91.44
Volume859.88K
Average Volume (3M)1.55M
Market Cap
$17.07B
Enterprise Value$16.87B
Total Cash (Recent Filing)$1.29B
Total Debt (Recent Filing)$1.09B
Price to Earnings (P/E)125.2
Beta0.77
Next Earnings
Apr 26, 2023EPS Estimate
$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.73
Shares Outstanding186,528,784
10 Day Avg. Volume1,535,783
30 Day Avg. Volume1,545,102
Standard Deviation0.09
R-Squared0.06
Alpha0.00444
Financial Highlights & Ratios
Price to Book (P/B)4.16
Price to Sales (P/S)8.07
Price to Cash Flow (P/CF)97.50
P/FCF Ratio381.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.05
Enterprise Value/Gross Profit10.46
Enterprise Value/Ebitda63.20
Forecast
1Y Price Target
$118.19Price Target Upside29.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
BioMarin Pharmaceutical News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMRN FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $70.73 and its highest was $117.77 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
Currently, no data Available
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Apr 26, 2023 which is in 28 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Feb 27, 2023. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.058 by $0.058.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is $0.15.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 186,528,780 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of $0 in its last earnings report, beating expectations of -$0.058. Following the earnings report the stock price went down -3.535%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Among the largest hedge funds holding BioMarin Pharmaceutical’s share is PRIMECAP Management Co. It holds BioMarin Pharmaceutical’s shares valued at 2B.
---
BioMarin Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$118.19 (29.25% Upside)
$118.19 (29.25% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 7.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $100.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.79%
12-Months-Change
Fundamentals
Return on Equity
3.19%
Trailing 12-Months
Asset Growth
6.19%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
---
Top 5 ETFs holding BMRN
Lyxor MSCI World (LUX) UCITS ETF
$31.36M
VanEck Biotech ETF
$15.08M
Ly FTSE 100 ETF Act. -Montly Hedged C USD-
$12.38M
Lyxor FTSE China A50 UCITS ETF
$1.37M
Desjardins SocieTerra American Equity ETF Trust Units
$28.97K
Up to five ETFs with an Outperform Smart Score that hold BMRN. The ETFs are listed according to market value of BMRN within the ETF
---
---